The DOI matches its Crossref record; 14 of the 14 references it cites were found in a registry or an index.
Five-Year Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma
Open accessAbstract
BACKGROUNDNivolumab plus ipilimumab or nivolumab alone resulted in longer progression-free and overall survival than ipilimumab alone in a trial involving patients with advanced melanoma.We now report 5-year outcomes in the trial. METHODSWe randomly assigned patients with previously untreated advanced melanoma to receive one of the following regimens: nivolumab (at a dose of 1 mg per kilogram of body weight) plus ipilimumab (3 mg per kilogram) every 3 weeks for four doses, followed by nivolumab (3 mg per kilogram every 2 weeks); nivolumab (3 mg per kilogram every 2 weeks) plus ipilimumab-matched placebo; or ipilimumab (3 mg per kilogram every 3 weeks for four doses) plus nivolumab-matched placebo.The two primary end points were progression-free survival and overall survival in the nivolumab-plus-ipilimumab group and in the nivolumab group, as compared with the ipilimumab group. RESULTSAt a minimum follow-up of 60 months, the median overall survival was more than 60.0 months (median not reached) in the nivolumab-plus-ipilimumab group and 36.9 months in the nivolumab group, as compared with 19.9 months in the ipilimumab group (hazard ratio for death with nivolumab plus ipilimumab vs. ipilimumab, 0.52; hazard ratio for death with nivolumab vs. ipilimumab, 0.63).Overall survival at 5 years was 52% in the nivolumab-plus-ipilimumab group and 44% in the nivolumab group, as compared with 26% in the ipilimumab group.No sustained deterioration of health-related quality of life was observed during or after treatment with nivolumab plus ipilimumab or with nivolumab alone.No new late toxic effects were noted. CONCLUSIONSAmong patients with advanced melanoma, sustained long-term overall survival at 5 years was observed in a greater percentage of patients who received nivolumab plus ipilimumab or nivolumab alone than in those who received ipilimumab alone, with no apparent loss of quality of life in the patients who received regimens containing nivolumab.(Funded by Bristol-Myers Squibb and others; CheckMate 067 ClinicalTrials.govnumber, NCT01844505.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Until now, the FDA has approved the ipilimumab plus nivolumab for melanoma, RCC, MSI-H/dMMR colorectal cancer, HCC, PD-L1 positive NSCLC, and malignant pleural mesothelioma (Table 5) [132–138].”
From Combination strategies with PD-1/PD-L1 blockade: current advances and future directions (2022) · cites this paper as [133]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“In many cancers, nivolumab in combination with ipilimumab improves response rates compared to either agent alone, but the combination has not been evaluated in childhood cancer.”
From A Phase I/II Trial of Nivolumab plus Ipilimumab in Children and Young Adults with Relapsed/Refractory Solid Tumors: A Children's Oncology Group Study ADVL1412 (2022) · cites this paper as [12]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Nivolumab, a PD-1 inhibitor, in combination with ipilimumab, a CTLA-4 inhibitor, has shown favourable efficacy outcomes and manageable safety profiles across multiple tumour types.”
From Nivolumab plus ipilimumab versus lenvatinib or sorafenib as first-line treatment for unresectable hepatocellular carcinoma (CheckMate 9DW): an open-label, randomised, phase 3 trial (2025) · cites this paper as [12]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“While immune checkpoint inhibitors (ICIs) have greatly enhanced clinical outcomes across multiple cancer types,1, 2, 3”
From irAE-GPT: leveraging large language models to identify immune-related adverse events in electronic health records and clinical trial datasets (2026) · cites this paper as [3]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“In unresectable or metastatic melanoma, overall survival at 5 years is 52% following nivolumab plus ipilimumab compared to 44% for nivolumab alone and 26% for ipilimumab alone12,13.”
The check wasn’t confident either way, so it gives no verdict — never disputed.
In the citing paper
“Melanomas and urothelial carcinomas that are intrinsically resistant to anti-PD-1/PD-L1 therapy show elevated TGF-β signaling, particularly in the stromal compartment of immune excluded tumors21,77,228,361.”
From TGFβ biology in cancer progression and immunotherapy (2021) · cites this paper as [361]
Experimental — accuracy not yet measuredThe check wasn’t confident either way, so it gives no verdict — never disputed.
In the citing paper
“Evidence for benefit of nivolumab plus ipilimumab compared to single agent ICI has also been demonstrated in patients with advanced renal cell cancer, microsatellite high/deficient mismatch repair (MSI-hi/dMMR) metastatic colorectal cancer12,14,15, hepatocellular carcinoma16, and non-small cell, EGFR/ALK wild type lung cancer17–19.”
From A Phase I/II Trial of Nivolumab plus Ipilimumab in Children and Young Adults with Relapsed/Refractory Solid Tumors: A Children's Oncology Group Study ADVL1412 (2022) · cites this paper as [12]
Experimental — accuracy not yet measuredIn the citing paper
“Multiple clinical trials with combined blockade of CTLA4 and PD-1/PD-L1 demonstrated higher response rates than either monotherapy, in different cancer types including melanoma ( 54, 55 ), hepatocellular carcinoma ( 56 ), renal cell carcinoma (RCC; refs.57, 58 ), NSCLC ( 59 ), malignant pleural mesothelioma ( 60 ), and colorectal cancer (MSI-H/dMMR; ref. 61 ).”
From The Next Decade of Immune Checkpoint Therapy (2021) · cites this paper as [55]
In the citing paper
“Long-term follow-up has demonstrated durable survival benefi t for a subset of patients with melanoma and RCC, and combination therapy with ICT is under active investigation for a number of tumor types ( 55,58 ).”
From The Next Decade of Immune Checkpoint Therapy (2021) · cites this paper as [55]
In the citing paper
“Anti-PD-1/PD-L1 agents pared with chemotherapy have also improved response rates and survival in many diseases including lung cancer, triple negative breast cancer, head and neck squamous cell carcinoma, and others.12–14”
From Endocrine toxicities of immune checkpoint inhibitors (2021) · cites this paper as [13]
In the citing paper
“The results of CheckMate-069, CheckMate-067, and CheckMate-142 showed that ipilimumab plus nivolumab significantly improved the outcomes of patients, relative to ipilimumab or nivolumab monotherapies [132–134].”
From Combination strategies with PD-1/PD-L1 blockade: current advances and future directions (2022) · cites this paper as [133]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma
Larkin, J., Chiarion-Sileni, V., Gonzalez, R., Grob, J. J., Cowey, C. L., Lao, C. D., Schadendorf, D., Dummer, R., Smylie, M., Rutkowski, P., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1504030 · Cited by 8,157
Self-citationOverall Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma
Wolchok, J. D., Chiarion-Sileni, V., Gonzalez, R., Rutkowski, P., Grob, J.-J., Cowey, C. L., Lao, C. D., Wagstaff, J., Schadendorf, D., Ferrucci, P. F., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1709684 · Cited by 5,357
Self-citation(1997) · doi:10.1097/00005650-199711000-00002 · Cited by 4,544
Hodi, F. S., Chiarion-Sileni, V., Gonzalez, R., Grob, J.-J., Rutkowski, P., Cowey, C. L., Lao, C. D., Schadendorf, D., Wagstaff, J., Dummer, R., et al. (2018) · The Lancet Oncology · doi:10.1016/s1470-2045(18)30700-9 · Cited by 1,399
Five-year outcomes with dabrafenib plus trametinib in metastatic melanoma
Robert, C., Grob, J. J., Stroyakovskiy, D., Karaszewska, B., Hauschild, A., Levchenko, E., Chiarion Sileni, V., Schachter, J., Garbe, C., Bondarenko, I., et al. (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1904059 · Cited by 1,389
Self-citationCombined Nivolumab and Ipilimumab in Melanoma Metastatic to the Brain
Tawbi, H. A., Forsyth, P. A., Algazi, A. P., Hamid, O., Hodi, F. S., Moschos, S. J., Khushalani, N. I., Lewis, K. D., Lao, C. D., Postow, M. A., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1805453 · Cited by 1,336
Self-citationLong, G. V., Atkinson, V. G., Lo, S., Sandhu, S. K., Guminski, A. D., Brown, M. P., Wilmott, J. S., Edwards, J. J., Gonzalez, M., Scolyer, R. A., et al. (2018) · The Lancet Oncology · doi:10.1016/s1470-2045(18)30139-6 · Cited by 1,001
Self-citationEstimation of minimally important differences in EQ-5D utility and VAS scores in cancer
Pickard, A. S., Neary, M. P., & Cella, D. F. (2007) · Health and Quality of Life Outcomes · doi:10.1186/1477-7525-5-70 · Cited by 932
Lebbé, C., Meyer, N., Mortier, L., Marquez-Rodas, I., Robert, C., Rutkowski, P., Menzies, A. M., Eigentler, T., Ascierto, P. A., Smylie, M., et al. (2019) · Journal of Clinical Oncology · doi:10.1200/jco.18.01998 · Cited by 408
Self-citationKhair, D. O., Bax, H. J., Mele, S., Crescioli, S., Pellizzari, G., Khiabany, A., Nakamura, M., Harris, R. J. C., French, E., Hoffmann, R. M., et al. (2019) · Frontiers in Immunology · doi:10.3389/fimmu.2019.00453 · Cited by 252
Cited by
Sorted by citations
Items 401–500 of 1,003
Watson, A., Goutam, S., Stukalin, I., Ewanchuk, B. W., Sander, M. S., Meyers, D. E., Pabani, A., Cheung, W. Y., Heng, D. Y. C., Cheng, T., et al. (2022) · JAMA Network Open · doi:10.1001/jamanetworkopen.2022.45596 · Cited by 69
Váraljai, R., Zimmer, L., Al-Matary, Y. S., Kaptein, P., Albrecht, L. J., Shannan, B., Brase, J. C., Gusenleitner, D., Amaral, T. M. S., Wyss, N., et al. (2023) · Nature Cancer · doi:10.1038/s43018-023-00610-2 · Cited by 70
Self-citationBaxi, V., Lee, G., Duan, C., Pandya, D., Cohen, D. N., Edwards, R., Chang, H., Li, J., Elliott, H., Pokkalla, H., et al. (2022) · Modern Pathology · doi:10.1038/s41379-022-01119-2 · Cited by 66
“Immuno-oncology therapies, including immune checkpoint inhibitors targeting programmed death-1/death ligand 1 (PD-[L]1) and cytotoxic T lymphocyte antigen-4, have improved clinical outcomes across many tumor types 1 – 3 .”
Lelliott, E. J., McArthur, G. A., Oliaro, J., & Sheppard, K. E. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.661737 · Cited by 65
Self-citationDrakaki, A., Dhillon, P. K., Wakelee, H. A., Chui, S. Y., Shim, J., Kent, M., Degaonkar, V., HOANG, T. N., McNally, V. A., Luhn, P., et al. (2020) · OncoImmunology · doi:10.1080/2162402x.2020.1824645 · Cited by 65
Marsavela, G., Lee, J., Calapre, L., Wong, S. Q., Pereira, M. R., McEvoy, A. C., Reid, A. L., Robinson, C., Warburton, L., Abed, A., et al. (2020) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-20-2251 · Cited by 66
Self-citationReynolds, A. C., & McKenzie, L. J. (2023) · Journal of Clinical Oncology · doi:10.1200/jco.22.01885 · Cited by 68
Combining nanomedicine and immune checkpoint therapy for cancer immunotherapy
Boone, C. E., Wang, L., Gautam, A., Newton, I. G., & Steinmetz, N. F. (2021) · Wiley Interdisciplinary Reviews Nanomedicine and Nanobiotechnology · doi:10.1002/wnan.1739 · Cited by 66
Dousset, L., Poizeau, F., Robert, C., Mansard, S., Mortier, L., Caumont, C., Routier, É., Dupuy, A., Rouanet, J., Battistella, M., et al. (2021) · JCO Precision Oncology · doi:10.1200/po.21.00084 · Cited by 71
“Although response rates (RR) are durable and remarkable, only approximately 35%-45% of patients benefit from these costly drugs, but no positive or negative predictive biomarkers are available to date to guide clinicians in the choice of specific therapies.(1,2,5) Tumor mutational burden (TMB, also known as mutation l…”
BackgroundSelf-citationJin, W., Yang, Q., Chi, H., Wei, K., Zhang, P., Zhao, G., Chen, S., Xia, Z., & Li, X. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.1025330 · Cited by 64
“For instance, although nivolumab renewed melanoma clinical treatment, about 39% of patients had progressed at the 5-year follow-up (8).”
BackgroundYin, N., Li, X., Zhang, X., Xue, S., Cao, Y., Niedermann, G., Lu, Y., & Xue, J. (2024) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-01826-z · Cited by 74
Melanoma recurrence patterns and management after adjuvant targeted therapy: a multicentre analysis
Bhave, P., Pallan, L., Long, G. V., Menzies, A. M., Atkinson, V. G., Cohen, J. V., Sullivan, R. J., Chiarion‐Sileni, V., Nyakas, M., Kähler, K. C., et al. (2020) · British Journal of Cancer · doi:10.1038/s41416-020-01121-y · Cited by 65
Self-citationCell Fate Reprogramming in the Era of Cancer Immunotherapy
Zimmermannova, O., Caiado, I., Ferreira, A. G., & Pereira, C.-F. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.714822 · Cited by 56
Melanoma and Vitiligo: In Good Company
Failla, C. M., Carbone, M. L., Fortes, C., Pagnanelli, G., & D’Atri, S. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20225731 · Cited by 64
Novel PD-1 inhibitor prolgolimab: expanding non-resectable/metastatic melanoma therapy choice
Tjulandin, S. A., Демидов, Л. В., Moiseyenko, V. M., Анатольевна, П. С., Semiglazova, Т. Y., Валентиновна, О. С., Zukov, R. A., Lazarev, S., Makarova, Y., Nechaeva, M., et al. (2021) · European Journal of Cancer · doi:10.1016/j.ejca.2021.02.030 · Cited by 63
Falchook, G. S., Peeters, M., Rottey, S., Dirix, L. Y., Obermannova, R. L., Cohen, J. E., Perets, R., Frommer, R. S., Bauer, T. M., Wang, J. S.-Z., et al. (2021) · Investigational New Drugs · doi:10.1007/s10637-021-01088-4 · Cited by 66
Targeting Cancer Cell Ferroptosis to Reverse Immune Checkpoint Inhibitor Therapy Resistance
Deng, J., Zhou, M. L., Liao, T., Kuang, W., Xia, H., Yin, Z., Tan, Q., Li, Y., Song, S., Zhou, E., et al. (2022) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2022.818453 · Cited by 63
Gordon, L. G., Leung, W. C. Y., Johns, R., McNoe, B., Lindsay, D., Merollini, K. M. D., Elliott, T. M., Neale, R. Ε., Olsen, C. M., Pandeya, N., et al. (2022) · International Journal of Environmental Research and Public Health · doi:10.3390/ijerph19063178 · Cited by 64
Molecular Frontiers in Melanoma: Pathogenesis, Diagnosis, and Therapeutic Advances
Kim, H. J., & Kim, Y. H. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25052984 · Cited by 69
The current landscape of single-cell transcriptomics for cancer immunotherapy
Guruprasad, P., Lee, Y. G., Kim, K. H., & Ruella, M. (2020) · The Journal of Experimental Medicine · doi:10.1084/jem.20201574 · Cited by 65
The Inflammatory Milieu of Adamantinomatous Craniopharyngioma and Its Implications for Treatment
Whelan, R., Prince, E. W., Gilani, A., & Hankinson, T. C. (2020) · Journal of Clinical Medicine · doi:10.3390/jcm9020519 · Cited by 63
Machiraju, D., Wiecken, M., Lang, N., Hülsmeyer, I., Roth, J., Schank, T. E., Eurich, R., Halama, N., Enk, A., & Hassel, J. C. (2021) · OncoImmunology · doi:10.1080/2162402x.2021.1926762 · Cited by 65
Impact of Patient Age on Clinical Efficacy and Toxicity of Checkpoint Inhibitor Therapy
Wong, S. K., Nebhan, C. A., & Johnson, D. B. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.786046 · Cited by 66
“(27) Nivolumab + ipilimumab vs ipilimumab Total – 629 5-year PFS rate 5-year OS rate”
BackgroundUnveiling the tumor immune microenvironment of organ-specific melanoma metastatic sites
Conway, J. W., Rawson, R. V., Lo, S., Ahmed, T., Vergara, I. A., Gide, T. N., Attrill, G. H., Carlino, M. S., Saw, R. P. M., Thompson, J. F., et al. (2022) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2022-004884 · Cited by 69
Self-citationShoushtari, A. N., Olszanski, A. J., Nyakas, M., Hornyak, T. J., Wolchok, J. D., Levitsky, V., Kuryk, Ł., Hansen, T. B., & Jaderberg, M. E. (2022) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-22-2046 · Cited by 62
“However, 36% to 66% of patients experience disease progression (PD) after combined or single-agent anti – PD-1 and anti – CTLA-4 therapy and require further treat-ment (1, 3).”
BackgroundSelf-citationDavies, D., Kamdar, S., Woolf, R., Zlatareva, I., Iannitto, M. L., Morton, C., Haque, Y., Martin, H., Biswas, D., Ndagire, S., et al. (2024) · Nature Cancer · doi:10.1038/s43018-023-00690-0 · Cited by 67
“Among myriad CPI modalities, those blocking interactions of programmed cell death protein 1 (PD-1) with its ligand, programmed death ligand 1 (PD-L1), have consistently been the most effective 3,4 .”
BackgroundRevitalizing T cells: breakthroughs and challenges in overcoming T cell exhaustion
Wu, Y., Wu, Y., Gao, Z., Yu, W., Zhang, L., & Zhou, F. (2026) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-025-02327-3 · Cited by 78
Hargadon, K. M. (2020) · Clinical and Translational Medicine · doi:10.1002/ctm2.37 · Cited by 63
Patrinely, J. R., Young, A. C., Quach, H., Williams, G. R., Ye, F., Fan, R., Horn, L., Beckermann, K. E., Gillaspie, E. A., Sosman, J. A., et al. (2020) · European Journal of Cancer · doi:10.1016/j.ejca.2020.05.005 · Cited by 61
Bergholz, J. S., Wang, Q., Kabraji, S. K., & Zhao, J. J. (2020) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-19-2300 · Cited by 58
Deacon, D. C., Smith, E. A., & Judson‐Torres, R. L. (2021) · Frontiers in Medicine · doi:10.3389/fmed.2021.642380 · Cited by 64
Klein, O., Kee, D., Markman, B., Carlino, M. S., Underhill, C. R., Palmer, J., Power, D., Cebon, J. S., & Behren, A. (2021) · Cancer Cell · doi:10.1016/j.ccell.2021.04.005 · Cited by 61
Self-citationThe Pan-Immune-Inflammation Value in Patients with Metastatic Melanoma Receiving First-Line Therapy
Fucà, G., Beninato, T., Bini, M., Mazzeo, L., Guardo, L. D., Cimminiello, C., Randon, G., Apollonio, G., Bisogno, I., Vecchio, M. D., et al. (2021) · Targeted Oncology · doi:10.1007/s11523-021-00819-0 · Cited by 60
Organoid models of the tumor microenvironment and their applications
Xia, T., Du, W., Chen, X., & Zhang, Y.-N. (2021) · Journal of Cellular and Molecular Medicine · doi:10.1111/jcmm.16578 · Cited by 63
Poels, K., Neppelenbroek, S. I. M., Kersten, M. J., Antoni, M. L., Lutgens, E., & Seijkens, T. T. P. (2021) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2021-002916 · Cited by 64
Nakamura, Y., Namikawa, K., Yoshikawa, S., Kiniwa, Y., Maekawa, T., Yamasaki, O., Isei, T., Matsushita, S., Nomura, M., Nakai, Y., et al. (2021) · ESMO Open · doi:10.1016/j.esmoop.2021.100325 · Cited by 61
“36 Partial response 37 (20) 30 (20) 7 (22) Stable disease 50 (27) 37 (24) 13 (41) Progressive disease 83 (45) 72 (48) 11 (34) Unable to determine 2 (1) 2 (1) 0 Urogenital tract Complete response 8 (11) 6 (11) 2 (10) 0.”
Association Between Sex and Immune Checkpoint Inhibitor Outcomes for Patients With Melanoma
Jang, S. R., Nikita, N., Banks, J., Keith, S. W., Johnson, J. M., Wilson, M. A., & Lu-Yao, G. L. (2021) · JAMA Network Open · doi:10.1001/jamanetworkopen.2021.36823 · Cited by 61
Immunotherapy in Glioblastoma: Current Approaches and Future Perspectives
Sener, U. T., Ruff, M. W., & Campian, J. L. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23137046 · Cited by 61
Jahn, A. S., Navarini, A. A., Cerminara, S. E., Kostner, L., Huber, S. M., Kunz, M., Maul, J., Dummer, R., Sommer, S., Neuner, A. D., et al. (2022) · Cancers · doi:10.3390/cancers14153829 · Cited by 62
Self-citationExosome-based nanoimmunotherapy targeting TAMs, a promising strategy for glioma
Luo, H., Zhang, H., Mao, J., Cao, H., Tao, Y., Zhao, G., Zhang, Z., Zhang, N., Liu, Z., Zhang, J., et al. (2023) · Cell Death and Disease · doi:10.1038/s41419-023-05753-9 · Cited by 63
“As a booming and promising therapeutic regimen, immunotherapy shows significant clinical value in a crowd of tumors like a subset of hematological malignancies, melanoma [21, 22], and non-small-cell lung cancer [23], etc.”
BackgroundBallotti, R., Chéli, Y., & Bertolotto, C. (2020) · Molecular Cancer · doi:10.1186/s12943-020-01290-7 · Cited by 63
Ma, X., Zhang, Y., Wang, S., Wei, H., & Yu, J. (2021) · Journal of Cancer · doi:10.7150/jca.49174 · Cited by 62
Cortellino, S., Quagliariello, V., Delfanti, G., Blaževitš, O., Chiodoni, C., Maurea, N., Mauro, A. D., Tatangelo, F., Pisati, F., Shmahala, A., et al. (2023) · Nature Communications · doi:10.1038/s41467-023-41066-3 · Cited by 66
The systemic hallmarks of cancer
Paul, D. (2020) · Journal of Cancer Metastasis and Treatment · doi:10.20517/2394-4722.2020.63 · Cited by 59
Hosein, A. N., Dangol, G., Okumura, T., Roszik, J., Rajapakshe, K., Siemann, M., Zaid, M., Ghosh, B., Monberg, M., Guerrero, P. A., et al. (2022) · Gastroenterology · doi:10.1053/j.gastro.2021.12.273 · Cited by 61
Association of Sociodemographic Factors With Immunotherapy Receipt for Metastatic Melanoma in the US
Moyers, J. T., Patel, A., Shih, W., & Nagaraj, G. (2020) · JAMA Network Open · doi:10.1001/jamanetworkopen.2020.15656 · Cited by 59
Frontiers in cancer immunotherapy—a symposium report
Cable, J., Greenbaum, B. D., Pe’er, D., Bollard, C. M., Bruni, S., Griffin, M. E., Allison, J. P., Wu, C. J., Subudhi, S. K., Mardis, E. R., et al. (2020) · Annals of the New York Academy of Sciences · doi:10.1111/nyas.14526 · Cited by 65
Appleton, E. S., Hassan, J., Hak, C. C. W., Sivamanoharan, N., Wilkins, A. C., Samson, A., Ono, M., Harrington, K. J., Melcher, A. A., & Wennerberg, E. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.754436 · Cited by 63
“5-month median duration of response in advanced melanoma (7).”
BackgroundJiang, J., Wang, W., Zheng, H., Chen, X., Liu, X., Xie, Q., Cai, X., Zhang, Z., & Li, R. (2022) · Biomaterials · doi:10.1016/j.biomaterials.2022.121561 · Cited by 60
18F FDG PET/CT and Novel Molecular Imaging for Directing Immunotherapy in Cancer
Hughes, D. J., Subesinghe, M., Taylor, B. P., Billè, A., Spicer, J. F., Papa, S., Goh, V., & Cook, G. (2022) · Radiology · doi:10.1148/radiol.212481 · Cited by 60
Fulgenzi, C. A. M., D’Alessio, A., Airoldi, C. A., Scotti, L., Demirtaş, C. Ö., Gennari, A., Cortellini, A., & Pinato, D. J. (2022) · European Journal of Cancer · doi:10.1016/j.ejca.2022.06.058 · Cited by 60
T-cell exhaustion and stemness in antitumor immunity: Characteristics, mechanisms, and implications
Chi, X., Luo, S., Ye, P., Hwang, W., Cha, J., Yan, X., & Yang, W. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1104771 · Cited by 62
Relatlimab: a novel drug targeting immune checkpoint LAG-3 in melanoma therapy
Su, J., Fu, Y., Cui, Z., Abıdın, Z. U., Yuan, J., Zhang, X., Li, R., & Zhao, C. (2024) · Frontiers in Pharmacology · doi:10.3389/fphar.2023.1349081 · Cited by 59
Moser, J. C., Chen, D., Hu‐Lieskovan, S., Grossmann, K. F., Patel, S. B., Colonna, S. V., Ying, J., & Hyngstrom, J. R. (2019) · Cancer Medicine · doi:10.1002/cam4.2625 · Cited by 59
Biomarkers of Immune Checkpoint Blockade Response in Triple-Negative Breast Cancer
Isaacs, J. M., Anders, C. K., McArthur, H. L., & Force, J. M. (2021) · Current Treatment Options in Oncology · doi:10.1007/s11864-021-00833-4 · Cited by 60
Cancer neoantigens as potential targets for immunotherapy
Ma, W., Pham, B., & Li, T. (2021) · Clinical & Experimental Metastasis · doi:10.1007/s10585-021-10091-1 · Cited by 63
Review of Current Principles of the Diagnosis and Management of Brain Metastases
Brenner, A. W., & Patel, A. J. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.857622 · Cited by 58
“In patients with melanoma and asymptomatic brain metastases, combination immunotherapy alone resulted in a three-year progression-free survival rate of 54% and an overall survival rate of 72%, without theneed for radiation therapy or surgery (15, 16).”
BackgroundMurphy, R., Halford, S. E. R., & Symeonides, S. N. (2023) · Frontiers in Oncology · doi:10.3389/fonc.2023.1144056 · Cited by 59
“An example of this is the addition of ipilimumab to nivolumab in metastatic melanoma, where nivolumab alone may be only marginally less effective but significantly better-tolerated (25).”
BackgroundJilani, S., Saco, J. D., Mugarza, E., Pujol-Morcillo, A., Chokry, J., Ng, C., Abril-Rodríguez, G., Berger-Manerio, D., Pant, A., Hu, J. G., et al. (2024) · Nature Communications · doi:10.1038/s41467-024-45221-2 · Cited by 60
Nanosystems for Improved Targeted Therapies in Melanoma
Beiu, C., Giurcăneanu, C., Grumezescu, A. M., Holban, A. M., Popa, L. G., & Grumezescu, A. M. (2020) · Journal of Clinical Medicine · doi:10.3390/jcm9020318 · Cited by 60
Leiter, U., Loquai, C., Reinhardt, L., Rafei-Shamsabadi, D. A., Gutzmer, R., Kaehler, K. C., Heinzerling, L., Hassel, J. C., Glutsch, V., Sirokay, J. D., et al. (2020) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2020-000897 · Cited by 59
Self-citationExpression of the Immune Checkpoint Regulators LAG-3 and TIM-3 in Classical Hodgkin Lymphoma
Halabi, L. E., Adam, J., Gravelle, P., Marty, V., Danu, A., Lazarovici, J., Ribrag, V., Bosq, J., Camara‐Clayette, V., Laurent, C., et al. (2020) · Clinical Lymphoma Myeloma & Leukemia · doi:10.1016/j.clml.2020.11.009 · Cited by 59
Subudhi, S. K., Siddiqui, B. A., Aparicio, A. M., Yadav, S. S., Basu, S., Chen, H., Jindal, S., Tidwell, R. S. S., Varma, A., Logothetis, C. J., et al. (2021) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2021-002919 · Cited by 58
Flieswasser, T., Loenhout, J. V., Boullosa, L. F., Eynde, A. V. D., Waele, J. D., Audenaerde, J. V. V., Lardon, F., Smits, E., Pauwels, P., & Jacobs, J. (2020) · Cells · doi:10.3390/cells9061474 · Cited by 50
Turiello, R., Capone, M., Giannarelli, D., Morretta, E., Monti, M. C., Madonna, G., Mallardo, D., Festino, L., Azzaro, R., Levesque, M. P., et al. (2020) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2020-001689 · Cited by 58
Self-citationShoushtari, A. N., Chatila, W. K., Arora, A., Sánchez-Vega, F., Kantheti, H. S., Zamalloa, J. A. R., Krieger, P., Callahan, M. K., Warner, A. B., Postow, M. A., et al. (2021) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-20-4189 · Cited by 56
Self-citationMelanoma: An update on systemic therapies
Skudalski, L., Waldman, R. A., Kerr, P. E., & Grant-Kels, J. M. (2021) · Journal of the American Academy of Dermatology · doi:10.1016/j.jaad.2021.09.075 · Cited by 57
Lechner, M. G., Patel, A. Y., Hugo, W., Angell, T. E., Cheng, M. I., Pioso, M. S., Hoang, A. T., Yakobian, N., McCarthy, E. C., Chen, H.-C., et al. (2022) · The Journal of Immunology · doi:10.4049/jimmunol.2200244 · Cited by 56
Chemotherapy in Cutaneous Melanoma: Is There Still a Role?
Pham, J. P., Joshua, A. M., da Silva, I. P., Dummer, R., & Goldinger, S. M. (2023) · Current Oncology Reports · doi:10.1007/s11912-023-01385-6 · Cited by 61
Self-citationChen, Y.-H., Chen, H.-H., Wang, W., Chen, H., Huang, W.-S., Kao, C.-H., Lee, S.-R., Yeat, N. Y., Yan, R.-L., Chan, S.-J., et al. (2023) · Nature Communications · doi:10.1038/s41467-023-38784-z · Cited by 57
“Immune checkpoint blockades (ICBs) targeting PD-1/PD-L1 or CTLA4 have revolutionized the current cancer therapy paradigm based on their high durability 1 – 3 .”
Goldinger, S. M., Buder‐Bakhaya, K., Lo, S., Forschner, A., McKean, M. A., Zimmer, L., Khoo, C. C. H., Dummer, R., Eroglu, Z., Buchbinder, E. I., et al. (2021) · European Journal of Cancer · doi:10.1016/j.ejca.2021.11.022 · Cited by 61
Self-citationCutaneous immune‐related adverse events in patients with melanoma treated with checkpoint inhibitors
Gault, A., Anderson, A. E., Plummer, R., Stewart, C. J., Pratt, A. G., & Rajan, N. (2021) · British Journal of Dermatology · doi:10.1111/bjd.19750 · Cited by 56
Current Melanoma Treatments: Where Do We Stand?
Moreira, A., Heinzerling, L. M., Bhardwaj, N., & Friedlander, P. A. (2021) · Cancers · doi:10.3390/cancers13020221 · Cited by 60
Li, M., Liu, D., Lee, D., Cheng, Y., Baumhover, N. J., Marks, B. M., Sagastume, E. A., Ballas, Z. K., Johnson, F. L., Morris, Z. S., et al. (2021) · Cancers · doi:10.3390/cancers13153676 · Cited by 58
Li, S., Wu, X., Yan, X., Zhou, L., Chi, Z., Si, L., Cui, C., Tang, B., Mao, L., Lian, B., et al. (2022) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2021-004036 · Cited by 56
Response to immune checkpoint inhibitors in acral melanoma: A nationwide cohort study
van Not, O. J., de Meza, M. M., van den Eertwegh, A. J. M., Haanen, J. B. A. G., Blank, C. U., Aarts, M. J. B., van den Berkmortel, F. W. P. J., van Breeschoten, J., de Groot, J. B., Hospers, G. A. P., et al. (2022) · European Journal of Cancer · doi:10.1016/j.ejca.2022.02.026 · Cited by 56
Self-citationTumor Immunogenic Cell Death as a Mediator of Intratumor CD8 T-Cell Recruitment
Roussot, N., Ghiringhelli, F., & Rébé, C. (2022) · Cells · doi:10.3390/cells11223672 · Cited by 55
Cancer organoids: A platform in basic and translational research
Ma, X., Wang, Q. L., Li, G., Li, H., Xu, S., & Pang, D. (2023) · Genes & Diseases · doi:10.1016/j.gendis.2023.02.052 · Cited by 62
Lim, W., Kao, H., Suteja, L., Li, C. H., Quah, H. S., Tan, D. S. W., Tan, S. H., Tan, E.-H., Tan, W.-L., Lee, J. N., et al. (2023) · Nature Communications · doi:10.1038/s41467-023-38407-7 · Cited by 60
“Combination PD-1/CTLA-4 inhibition has proven effective in several tumor types, improving on responses to single-agent ICB-therapy, and is now standard of care in malignant melanoma 27 and renal cell carcinoma 28 .”
Predictive Biomarkers of Immune Checkpoint Inhibition in Gastroesophageal Cancers
Sundar, R., Smyth, E. C., Peng, S., Yeong, J. P.-S., & Tan, P. B. O. (2020) · Frontiers in Oncology · doi:10.3389/fonc.2020.00763 · Cited by 55
Future role for adoptive T-cell therapy in checkpoint inhibitor-resistant metastatic melanoma
Borch, T. H., Andersen, R. S., Ellebæk, E., Met, Ö., Donia, M., & Svane, I. M. (2020) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2020-000668 · Cited by 56
Arangalage, D., Degrauwe, N., Michielin, O. A., Monney, P. A., & Özdemir, B. C. (2021) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2021.102282 · Cited by 56
Immunotherapy-related adverse effects on 18F-FDG PET/CT imaging
Gandy, N., Arshad, M., Wallitt, K. L., Dubash, S., Khan, S., & Barwick, T. D. (2020) · British Journal of Radiology · doi:10.1259/bjr.20190832 · Cited by 55
Resistance to immune checkpoint inhibitors in advanced gastro-oesophageal cancers
Baxter, M. A., Middleton, F., Cagney, H. P., & Petty, R. (2021) · British Journal of Cancer · doi:10.1038/s41416-021-01425-7 · Cited by 54
The Role of Glycosylation in Melanoma Progression
Vellis, C. D., Pietrobono, S., & Stecca, B. A. (2021) · Cells · doi:10.3390/cells10082136 · Cited by 56
Balasubramanian, A., John, T., & Asselin-Labat, M.-L. (2022) · Biochemical Society Transactions · doi:10.1042/bst20210961 · Cited by 61
The Dark Side of Melanin Secretion in Cutaneous Melanoma Aggressiveness
Cabaço, L. C., Tomás, A., Pojo, M., & Barral, D. C. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.887366 · Cited by 60
“Recently, the 5-year overall survival of patients receiving a combination of nivolumab and ipilimumab was documented to be 52% (24).”
BackgroundJiang, M., Hu, Y., Lin, G., & Chen, C. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.906251 · Cited by 59
“Even more, it has been hypothesized that discontinuation of treatment due to severe irAE could itself serve as a biomarker of strong immune response and thus predict efficacy (103, 105, 106).”
BackgroundMa, Y., Wang, T., Zhang, X., Wang, P., & Long, F. (2024) · Cell Death and Disease · doi:10.1038/s41419-024-06698-3 · Cited by 59
“For example, anti-PD-1/L1 therapy combined with anti-CTLA4 has become the standard for the treatment of melanoma, and the combination of nivolumab and ipilimumab in patients with advanced melanoma can improve the survival rate of patients of 5 years [51].”
BackgroundLi, M., Sack, J., Rahma, O. E., Hodi, F. S., Zucker, S. D., & Grover, S. (2020) · Cancer · doi:10.1002/cncr.33165 · Cited by 57
Self-citationHow Should We Test for Lynch Syndrome? A Review of Current Guidelines and Future Strategies
Gallon, R., Gawthorpe, P., Phelps, R., Hayes, C. M., Borthwick, G. M., Santibanez‐Koref, M., Jackson, M. S., & Burn, J. (2021) · Cancers · doi:10.3390/cancers13030406 · Cited by 57
Postow, M. A., Goldman, D. A., Shoushtari, A. N., Warner, A. B., Callahan, M. K., Momtaz, P., Smithy, J. W., Naito, E., Cugliari, M. K., Raber, V., et al. (2021) · Journal of Clinical Oncology · doi:10.1200/jco.21.01570 · Cited by 57
“Shortening the induction course of nivo 1 ipi to two doses on the basis of the proposed FATE metric did not reduce the rate of grade 3-4 treatment-related adverse events nor lead to any measurable reduction in the use of immunosuppression or treatment-related fatality compared with prior studies.(1,11) These unexpecte…”
BackgroundResultSelf-citationAttrill, G. H., Owen, C. N., Ahmed, T., Vergara, I. A., Colebatch, A. J., Conway, J. W., Nahar, K. J., Thompson, J. F., da Silva, I. P., Carlino, M. S., et al. (2022) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2022-004771 · Cited by 57
Self-citationChanges in survival in de novo metastatic cancer in an era of new medicines
Luyendijk, M., Visser, O. J., Blommestein, H. M., de Hingh, I. H. J. T., Hoebers, F. J. P., Jager, A., Sonke, G. S., de Vries, E. G. E., Groot, C. A. U., & Siesling, S. (2023) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djad020 · Cited by 54
“ICIs represent particularly important breakthroughs, improving the 5-year survival from metastatic melanoma by up to 52% in RCTs from historic levels less than 10% (22,23).”
BackgroundTeng, Y.-S., & Yu, S. (2023) · Current Oncology · doi:10.3390/curroncol30070498 · Cited by 57
Additivity predicts the efficacy of most approved combination therapies for advanced cancer
Hwangbo, H., Patterson, S. C., Dai, A., Plana, D., & Palmer, A. C. (2023) · Nature Cancer · doi:10.1038/s43018-023-00667-z · Cited by 56
Nano-formulations in disease therapy: designs, advances, challenges, and future directions
Shi, Y., Li, X., Li, Z., Sun, J., Gao, T., Wei, G., & Guo, Q. (2025) · Journal of Nanobiotechnology · doi:10.1186/s12951-025-03442-7 · Cited by 58
“For instance, the combination therapy of Nivolumab (a PD-1 inhibitor) and Ipilimumab (a CTLA-4 inhibitor) has demonstrated remarkable efficacy in multiple tumor types, including melanoma, colo-rectal cancer (CRC), and NSCLC [123–125].”
RP1 Combined With Nivolumab in Advanced Anti–PD-1–Failed Melanoma (IGNYTE)
Wong, M. K., Milhem, M. M., Sacco, J. J., Michels, J., In, G. K., Muñoz‐Couselo, E., Schadendorf, D., Beasley, G. M., Niu, J., Chmielowski, B., et al. (2025) · Journal of Clinical Oncology · doi:10.1200/jco-25-01346 · Cited by 54
Self-citationMina, D. S., Au, D., Brunet, J., Jones, J. M., TOMLINSON, G. A., Taback, N., Field, D., Berlingeri, A., Bradley, H., & Howell, D. (2017) · Current Oncology · doi:10.3747/co.23.3585 · Cited by 55
Rational use of 18F-FDG PET/CT in patients with advanced cutaneous melanoma: A systematic review
Bisschop, K., de Heer, E. C., Brouwers, A. H., Hospers, G. A. P., & Jalving, M. (2020) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2020.103044 · Cited by 56
Metadata
- Authors
- Larkin, J., Chiarion-Sileni, V., Gonzalez, R., Grob, J.-J., Rutkowski, P., Lao, C. D., Cowey, C. L., Schadendorf, D., Wagstaff, J., Dummer, R., Ferrucci, P. F., Smylie, M., Hogg, D., Hill, A., Márquez-Rodas, I., Haanen, J., Guidoboni, M., Maio, M., Schöffski, P., Carlino, M. S., Lebbé, C., McArthur, G., Ascierto, P. A., Daniels, G. A., Long, G. V., Bastholt, L., Rizzo, J. I., Balogh, A., Moshyk, A., Hodi, F. S., & Wolchok, J. D.
- Affiliations
- Royal Marsden NHS Foundation Trust (GB)
- From the Royal Marsden NHS Foundation Trust, London (J.L.), and the College of Medicine, Swansea University, Swansea (J.W.) — both in the United Kingdom; the Oncology Institute of Veneto IRCCS, Padua (V.C.-S.), the European Institute of Oncology, IRCCS, Milan (P.F.F.), Istituto Nazionale Tumori IRCCS Fondazione Pascale, Naples (P.A.A.), the Immunotherapy and Somatic Cell Therapy Unit, IRCCS Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori, Meldola (M.G.), and the Center for Immuno...
- University of Siena (IT)
- The University of Sydney (AU)
- ORCID
- Larkin, James
- Gonzalez, Rene
- Grob, Jean-Jacques
- Rutkowski, Piotr
- Schadendorf, Dirk
- Wagstaff, John
- Dummer, Reinhard
- Ferrucci, Pier F.
- Smylie, Michael
- Hogg, David
- Haanen, John
- Guidoboni, Massimo
- Maio, Michele
- Schöffski, Patrick
- Carlino, Matteo S.
- McArthur, Grant
- Ascierto, Paolo A.
- Daniels, Gregory A.
- Long, Georgina V.
- Bastholt, Lars
- Moshyk, Andriy
- Hodi, F. Stephen
- Wolchok, Jedd D.
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2019-10-17
- Volume
- 381
- Issue
- 16
- Pages
- 1535-1546
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W3043703771
- Cited by
- 3,723
- References
- 14
- Citations by year
- 2026: 257 · 2025: 366 · 2024: 560 · 2023: 656 · 2022: 693 · 2021: 712 · 2020: 453 · 2019: 18
- FWCI
- 195.72
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- Zurich Open Repository and Archive (University of Zurich) (acceptedVersion, other-oa)
- University of Southern Denmark Research Portal (University of Southern Denmark) (submittedVersion, other-oa)
- Universitätsbibliographie, Universität Duisburg-Essen (submittedVersion)
- Lirias (submittedVersion)
- Institutional Research Information System University of Ferrara (University of Ferrara) (submittedVersion, other-oa)
- Use Siena air (University of Siena) (submittedVersion)
- Zurich Open Repository and Archive (University of Zurich) (submittedVersion, other-oa)
- Zurich Open Repository and Archive (University of Zurich)
- Funders
- Amgen
- Bristol-Myers Squibb
- Eli Lilly and Company
- Pfizer
- AstraZeneca
- GlaxoSmithKline
- Sanofi
- Array BioPharma
- Regeneron Pharmaceuticals
- Massachusetts Medical Society
- Les Laboratories Pierre Fabre
- Incyte
- Syndax Pharmaceuticals
- National Institute for Health and Care Research
- Eisai
- Ipsen
- Plexxikon
- EUSA Pharma
- LEO Pharma
- Genentech
- EMD Serono
- Sanofi Genzyme
- Pharmacyclics
- National Cancer Institute (P30CA008748)
- Topics
- Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
- Health Sciences › Medicine › Oncology › Cutaneous Melanoma Detection and Management
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Melanoma and MAPK Pathways
- Keywords
- ipilimumab, advanced melanoma, combination immunotherapy, immune checkpoint inhibitors, five-year survival, overall survival, progression-free survival, long-term outcomes, health-related quality of life, CheckMate 067, PD-1 inhibitors, CTLA-4 inhibitors, immune-related adverse events
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
